Life Sciences BPO Market: Key Trends
Due to the looming patent expiry, healthcare spending cuts, and decline in productive outcome of research and development, pharmaceutical giants are seeking services from contract manufacturing organizations (CMOs) and contract research organizations (CROs) solutions. As per Transparency Market Research (TMR), outsourcing noncore business activities will allow pharma companies to focus on their core competencies. Besides this, life sciences BPO services also enable companies to optimally utilize their available resources.
Developed countries have currently emerged as major contributors to the global life sciences BPO market. The technological advancements witnessed in these countries have helped the pharmaceutical outsourcing to significantly evolve in the last few years. Furthermore, the rising opportunities in emerging economies such as India and China will further boost the global life sciences BPO market at 8.9% CAGR between 2015 and 2023.
TMR pegs the global life sciences market to reach US$286.3 bn by the end of 2023. The market was valued at US$127.4 bn in 2014.
High Prevalence of Chronic Ailments Puts North America at Forefront of Global Life Sciences BPO Market
North America, Asia Pacific, Europe, and Rest of the World constitute the key regional segments of the global life sciences BPO market. Among these regions, North America emerged dominant in the market with a share of 38.6% in 2014. The U.S. and Canada have emerged as the most lucrative markets for life sciences BPO in the region. The increasing pool of geriatric patients and the high prevalence of chronic ailments are key factors bolstering opportunities for outsourcing in the pharmaceutical sector in North America. Additionally, with the expectation of healthcare spending to increase in the forthcoming years, North America is expected to demonstrate lucrative growth prospects for the life sciences BPO market.
The North America life sciences BPO market stood at US$49.1 bn in 2014. Rising at a CAGR of 6.2%, the market is expected to reach US$88.8 bn by the end of 2023. Europe, on the other hand, has emerged as the second largest market for life sciences BPO in 2014. The rising demand for biosimilar drugs is expected to boost the market for life sciences BPO in the region.
However, TMR expects Asia Pacific to demonstrate the highest CAGR of 14.6% between 2015 and 2023. The high prices of raw materials, increasing pricing pressure, and the need for reducing cost have compelled various multinational pharmaceutical companies to outsource some of their business activities to developing nations. Services offered by CMOs and CROs in emerging economies offer substantial cost saving advantage. This in turn fuels demand from the life sciences BPO market in Asia Pacific.
Rising Clinical Trials to Boost Demand for Services from CROs
Based on services, the life sciences BPO market can be segmented into CMO, CRO, and contract sales and marketing organizations (CSO). Of these, CMOs held the lion’s share in the market in 2014. The increasing demand for generic products across developing markets and year-on-year rise in R&D investments by leading companies have been fuelling demand for services from CMOs for the past few years. TMR forecasts the CMO segment to exhibit a CAGR of 7.3% from 2015 and 2023.
However, during the forecast period, the CRO segment is poised to witness stronger growth. As per TMR, rising demand for outsourcing services related to drug discovery, clinical data management, pharmacovigilance, clinical trials, and regulatory consulting will boost the CRO segment at a CAGR of 9.3% during the forecast period.
Some of the leading companies operating in the global life sciences BPO market include Accenture plc, Boehringer Ingelheim GmbH, Anthelio Healthcare Solutions, Cognizant Technology Solutions, Catalent, Inc., PAREXEL International Corporation, International Business Machines Corporation, and others
The life sciences BPO market comprises services offered by CMOs (Contract Manufacturing Organizations) and CROs (Contract Research Organizations) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies.
Each of the segments has been analyzed in detail for market trends, recent developments, outlook, and opportunities. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that currently have strong impact on the global life sciences BPO market and could influence the market in the future as well. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition between leading market players operating across the globe. Porter’s five forces analysis is also explained in this section to understand the market considering different parameters that have an impact on the sustainability of the companies operating in the market. Additionally, a detailed value chain analysis for different components of the CRO and CMO have been covered to provide a comprehensive view of the industry. The report also mentioned about leading players for each of the sub-segments such as clinical trial, API manufacturing, vaccines, injectable among others.
All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their respective market shares. The recommendations section included in the report would assist existing market players in targeting all major stake holders of this industry such as companies, payers, providers, patients, government agencies and also to those aiming to seek an entry. The report also profiles major players in the global life sciences BPO market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments.
Key players in the life sciences BPO market include: Accenture plc, Anthelio Healthcare Solutions, Boehringer Ingelheim GmbH, Catalent, Inc., Cognizant Technology Solutions, Covance, Inc. Genpact Limited, ICON plc, Infosys Limited, International Business Machines Corporation, Lonza Group, PAREXEL International Corporation, Quintiles Transnational Corporation, and Wipro Limited.
The Global Life Sciences BPO market has been segmented as follows:
- Global Life Sciences BPO Market, by Services
- Pharmaceutical outsourcing
- Contract Research Organizations
- Drug Discovery
- Preclinical Studies
- Clinical Trials
- Medical Writing
- Pharmacovigilance
- Clinical Data Management
- Regulatory Services
- Clinical Monitoring
- Biostatistics
- Protocol Development
- Site Management
- Contract Manufacturing Organizations
- Active Pharmaceutical Ingredients
- Finished Dose Form Manufacturing
- Packaging
- Contract Sales and Marketing Organizations
- Contract Research Organizations
- Others (Payers and Providers)
- Pharmaceutical outsourcing
- Global Life Sciences BPO Market, by Geography
- North America
- United States
- Canada
- Europe
- United Kingdom
- Germany
- Rest of the Europe
- Asia Pacific
- China
- India
- Rest of the World
- Latin America
- Middle East and Africa
- North America
